Thomas B. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva. Thomas Cueni represents the innovative biopharmaceutical industry on the ACT Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Thomas Cueni has been instrumental in creating the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance. Prior to joining IFPMA he was Secretary General of Interpharma (Switzerland) and was a member of the Board and Chair of the European Federation of Pharmaceutical Industries and Associations. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He served as a Swiss diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).